Is NovaBay Pharmaceuticals Inc. (AMEX: NBY) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for NovaBay Pharmaceuticals Inc. (NBY) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.0017, or +1.39%, to $0.1244. Volume reached 27,854 shares, with price reaching a high of $0.1385 and a low of $0.112. Most recently, Yahoo Finance reported about the stock as it publicized that NovaBay Pharmaceuticals CEO Issues Letter to Stockholders.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored

Stocks Info

NBY belongs to the Healthcare sector of the AMEX while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.12 and fluctuated between $0.1299 as its day high and $0.1160 as its day low. The current market capitalization of NovaBay Pharmaceuticals Inc. is $6.81M. A total of 1.22 million shares were traded on the day, compared to an average of 764.52K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NBY has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 19 BUYs and 0 SELLs from insiders. Insiders purchased 1,235,222 shares during that period but sold 0.

In the most recent transaction, Hall Justin bought 10,000 shares of NBY for 0.15 per share on Sep 14. After the transaction, the CEO, GC and Director now owns 83,172 company shares. In a previous transaction on Sep 14, Kunin Jeffrey sold 291,368 shares at 0.16 per share. NBY shares that President, DERMAdoctor, LLC owns now total 208,632.

Among the insiders who sold shares, Kunin Audrey disposed of 291,368 shares on Sep 14 at a per-share price of $0.16. This resulted in the Chief Product Officer holding 208,632 shares of NBY after the transaction. In another insider transaction, Hall Justin bought 69,767 shares at $0.43 per share on Dec 06. Company shares held by the CEO, GC and Director now total 73,172.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NBY in the last 3 months, the mean price target is $2.80 with high estimates of $3.75 and low estimates of $1.85. In terms of 52-week highs and lows, NBY has a high of $0.77 and a low of $0.12.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NBY’s latest balance sheet shows that the firm has $7.50M in Cash & Short Term Investments as of fiscal 2021. There were $551.00k in debt and $3.44M in liabilities at the time. Its Book Value Per Share was $0.29, while its Total Shareholder’s Equity was $10.17M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 2 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NBY is Buy with a score of 5.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

292
294

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.